Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y6B6
UPID:
SAR1B_HUMAN
Alternative names:
GTP-binding protein B
Alternative UPACC:
Q9Y6B6; D3DQA4; Q567T4
Background:
GTP-binding protein SAR1b, also known as GTP-binding protein B, plays a pivotal role in the transport from the endoplasmic reticulum to the Golgi apparatus. It is activated by the guanine nucleotide exchange factor PREB and is crucial in the selection of protein cargo and the assembly of the COPII coat complex. SAR1b, in synergy with the cargo receptor SURF4, regulates the export of lipoproteins from the endoplasmic reticulum, maintaining lipid homeostasis.
Therapeutic significance:
SAR1b is directly linked to Chylomicron retention disease, an autosomal recessive disorder characterized by severe fat malabsorption, failure to thrive in infancy, and a deficiency in fat-soluble vitamins. Understanding the role of SAR1b could open doors to potential therapeutic strategies for this condition.